LB948 Oral cannabidiol treatment of seborrheic dermatitis in patients with Parkinson’s disease

Abstract

Seborrheic dermatitis (SD) is a common skin condition highly associated with the progressive neurogenerative disorder Parkinson’s disease (PD). Conventional SD treatment typically includes topical agents; however, recent evidence suggests oral cannabidiol (CBD) may simultaneously ameliorate neurologic symptoms of PD while reducing the increased sebum production involved in SD pathogenesis. As part of a larger PD patient study, CBD treatment for SD was investigated with a parallel, double-blind randomized controlled trial collecting facial images before and after a 3-week treatment with 2.5mg/kg/day oral CBD solution (n=29) or placebo (n=29).